

1 **Full Title:** Automated, standardized, quantitative analysis of cardiovascular borders on chest X-rays
2 using deep learning for assessing cardiovascular disease

3

4 **Running Title:** Quantitative analysis of cardiovascular borders on X-ray

5

6 **Authors:** June-Goo Lee, PhD¹; Tae Joon Jun, PhD²; Gyujun Jeong, MS¹; Hongmin Oh, MS⁴; Sijoon
7 Kim, MS¹; Heejun Kang, MS²; Jung Bok Lee, PhD²; Hyun Jung Koo, MD⁴; Jong Eun Lee, MD⁴;
8 Joon-Won Kang, MD⁴; Yura Ahn, MD⁴; Sang Min Lee, MD⁴; Joon Beom Seo, MD⁴; Seong Ho Park,
9 MD⁴; Min Soo Cho, MD⁵; Jung-Min Ahn, MD⁵; Duk-Woo Park, MD⁵; Joon Bum Kim, MD⁶; Cherry
10 Kim, MD⁷; Young Joo Suh, MD⁸; Iksung Cho, MD⁹; Marly van Assen, MD¹⁰; Carlo N. De Cecco,
11 MD¹⁰; Eun Ju Chun, MD¹¹; Young-Hak Kim, MD⁵; and Dong Hyun Yang, MD⁴ for the ADC
12 Investigators

13

14 **Author Affiliations:**

- 15 1. Biomedical Engineering Research Center, Asan Institute for Life Sciences, Asan Medical Center,
16 Seoul, Korea
- 17 2. Big Data Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea
- 18 3. Department of Clinical Epidemiology and Biostatistics, Asan Medical Center
- 19 4. Department of Radiology, Research Institute of Radiology, Asan Medical Center, University of
20 Ulsan College of Medicine, Seoul, Korea
- 21 5. Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul,
22 Korea
- 23 6. Department of Cardiothoracic Surgery, Asan Medical Center, University of Ulsan College of
24 Medicine, Seoul, Korea
- 25 7. Department of Radiology, Korea University Ansan Hospital, Ansan, Korea
- 26 8. Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul,
27 Korea
- 28 9. Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

29 10. Translational Laboratory for Cardiothoracic Imaging and Artificial Intelligence, Emory University

30 School of Medicine, Atlanta, GA, USA

31 11. Department of Radiology, Seoul National University Bundang Hospital, Seongnam, Korea

32

33 **Address for correspondence:**

34 Dong Hyun Yang, MD, PhD

35 Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88,

36 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea;

37 E-mail: donghyun.yang@gmail.com or donghyun.yang@amc.seoul.kr

38

39 Young-Hak Kim, MD, PhD

40 Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, 88,

41 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea;

42 E-mail: mdyhkim@amc.seoul.kr

43

44 **Word Count:** 2968

45 **No. of Tables:** 1

46 **No. of Figures:** 6

47 **No. of Supplementary Tables:** 18

48 **No. of Supplementary Figures:** 26

1 **What is already known on this topic?**

2 Previous deep learning research in the diagnosis of cardiovascular disease using chest X-rays has
3 focused on predicting specific disease categories, forecasting cardiovascular outcomes, and
4 automatically measuring the cardiothoracic (CT) ratio. The end-to-end learning methods that predict
5 disease categories or outcomes are typically limited to specific conditions and often lack explainability.
6 While the CT ratio is traditionally used in chest X-ray analysis, it often lacks well-defined normal
7 ranges and may not effectively detect conditions such as aortic dilatation or pulmonary trunk
8 enlargement.

9 **What this study adds**

10 To the best of our knowledge, this is the first study to propose age- and sex-specific normal values for
11 all cardiovascular borders (CVBs) as well as the CT ratio. Utilizing 96,129 normal chest X-rays from
12 multiple centers, we have established normal ranges for CVBs and standardized these values into z-
13 score mapping. This approach simplifies and enhances the practicality of clinical application. The z-
14 score mapping of CVBs has demonstrated clinical utility in diagnosing and categorizing diseases, as
15 well as in predicting prognosis. The AI software that automatically analyzes CVBs from CXR is
16 available for external validation and free trial use through our dedicated research website
17 (www.adcstudy.com). This study has transformed the interpretation of cardiovascular configuration on
18 chest X-ray from subjective expert assessments to objective, quantifiable, and standardized
19 measurements expressed as z-scores.

20
21

22 **ABSTRACTS**

23 **OBJECTIVE**

24 The analysis of cardiovascular borders (CVBs) on chest X-rays (CXRs) has traditionally relied on
25 subjective assessment, and the cardiothoracic (CT) ratio, its sole quantitative marker, does not reflect
26 great vessel changes and lacks established normal ranges. This study aimed to develop a deep
27 learning-based method for quantifying CVBs on CXRs and to explore its clinical utility.

28 **DESIGN**

29 Diagnostic/prognostic study

30 **SETTING**

31 Pre-validated deep learning for quantification and z-score standardization of CVBs: the superior vena
32 cava/ascending aorta (SVC/AO), right atrium (RA), aortic arch, pulmonary artery, left atrial
33 appendage (LAA), left ventricle (LV), descending aorta, and carinal angle.

34 **PARTICIPANTS**

35 A total of 96,129 normal CXRs from 4 sites were used to establish age- and sex-specific normal
36 ranges of CVBs. The clinical utility of the z-score analysis was tested using 44,567 diseased CXRs
37 from 3 sites.

38 **MAIN OUTCOMES MEASURES**

39 The area under the curve (AUC) for detecting disease, differences in z-scores for classifying subtypes,
40 and hazard ratio (HR) for predicting 5-year risk of death or myocardial infarction.

41 **RESULTS:** A total of 44,567 patients with disease (9964 valve disease; 32,900 coronary artery
42 disease; 1299 congenital heart disease; 294 aortic aneurysm; 110 mediastinal mass) were analyzed.
43 For distinguishing valve disease from normal controls, the AUC for the CT ratio was 0.79 (95% CI,
44 0.78-0.80), while the combination of RA and LV had an AUC of 0.82 (95% CI, 0.82-0.83). Between
45 mitral and aortic stenosis, z-scores of CVBs were significantly different in LAA (1.54 vs. 0.33,
46 $p < 0.001$), carinal angle (1.10 vs. 0.67, $p < 0.001$), and SVC/AO (0.63 vs. 1.02, $p < 0.001$), reflecting
47 distinct disease pathophysiology (dilatation of LA vs. AO). CT ratio was independently associated
48 with a 5-year risk of death or myocardial infarction in the coronary artery disease group (z-score ≥ 2 ,

49 adjusted HR 3.73 [95% CI, 2.09-6.64], reference z-score <-1).

50 **CONCLUSIONS**

51 Fully automated, deep learning-derived z-score analysis of CXR showed potential in detecting,
52 classifying, and stratifying the risk of cardiovascular abnormalities. Further research is needed to
53 determine the most beneficial clinical scenarios for this method.

54

55 **INTRODUCTION**

56 Advancements in artificial intelligence (AI) have significantly changed the way chest X-rays (CXR)
57 are analyzed, enabling the automatic diagnosis of diseases affecting the lungs, pleura, and bones.¹⁻³
58 Recent studies have also demonstrated AI's potential in cardiovascular disease for diagnosing heart
59 failure, predicting cardiovascular disease risks, and identifying various types of valvular diseases using
60 CXRs.⁴⁻⁸ AI systems trained to predict cardiovascular abnormalities in CXRs can provide saliency
61 maps for their explainability, which highlight the areas focused on making diagnoses.^{5,7} However, it is
62 important to note that these heatmaps might have limitations, particularly in pinpointing specific
63 abnormalities or diagnosing rare diseases.⁹

64 The cardiothoracic (CT) ratio, a traditional metric derived from CXRs, often lacks specific
65 reference values and may not effectively reveal changes in cardiovascular borders (CVBs) such as
66 dilatation of the aorta or pulmonary trunk.^{10,11} We have developed a fully automated, deep learning-
67 based software that analyzes CVBs comprehensively.¹² This AI software might offer us an opportunity
68 to establish precise normal ranges and detect various patterns of CVB enlargement associated with
69 cardiovascular diseases. Z-scores, which represent the number of standard deviations a data point is
70 from the mean of a normally distributed population, are frequently used to compare quantitative test
71 results with reference data. The precise normal ranges of CVBs may help the standardization of all
72 CVBs into simple z-scores for newly inputted CXRs. We therefore conducted the ADC (“Automated
73 Diagnosis of Cardiovascular abnormalities using chest X-ray”) study to develop a deep learning-based
74 method for quantifying CVBs on CXRs and to explore its clinical utility.

75

76 **METHODS**

77 **Study design**

78 The ADC was a retrospective, multicenter study initiated by investigators and included 140,696 CXRs
79 from three academic centers in two countries (South Korea, USA), as well as two public US datasets.¹³
80 ¹⁴ The study protocol received ethical approval from the Institutional Review Boards of all
81 participating institutions, and informed consent was waived for all participants (Asan Medical Center,
82 Seoul, Korea; 2023-1001; Severance Hospital, Seoul, Korea; 4-2020-0628; Emory University, Atlanta,
83 GA; STUDY00005513). The study design is summarized in **Figure 1**. Briefly, we utilized a pre-
84 validated deep learning model to automatically delineate CVBs on 96,129 normal CXRs.¹² This deep
85 learning-based analysis enabled the quantification of CVBs and the establishment of age- and sex-
86 specific normal ranges for both Korea and the USA. These normal ranges facilitated the
87 standardization of individual CVBs into simple z-scores for newly inputted CXRs (**Figure 2**). The
88 clinical utility of the z-score mapping was evaluated across various disease groups, including valvular
89 heart disease (VHD), coronary artery disease (CAD), congenital heart disease (CHD), aortic aneurysm,
90 and mediastinal mass.

91

92 **Study cohorts**

93 The normal cohorts used to establish reference ranges of CVBs encompassed data from Asan Medical
94 Center (Seoul, Korea) labeled as “Normal Korean” (n=71,493) and three American datasets
95 collectively labeled as “Normal American” (n=24,636). The dataset from Asan Medical Center
96 spanned from 2002 to 2016, including 428,000 individuals who underwent both CXR and
97 transthoracic echocardiography within a six-month period, with 71,493 meeting the criteria for
98 normality in both tests (eTable 1 and eFigure 1 in Supplement) . Data extraction and analysis were
99 performed by the Big Data Research Center at Asan Medical Center utilizing the CardioNet database,
100 a meticulously curated database integrated within the electronic health records.¹⁵ The selection criteria
101 for normal CXRs involved a comprehensive review of structured echocardiography records,
102 radiological reports, and international classification of disease codes, carefully excluding any cases
103 indicative of cardiac, pleuropulmonary diseases, or skeletal anomalies such as scoliosis. The Normal

104 American dataset was derived from two publicly accessible datasets—one from the National Institutes
105 of Health Clinical Center (NIH subgroup)¹³ and another from Stanford University Hospital (CheXpert
106 Subgroup)¹⁴—as well as a dataset from Emory University Medical Center, Atlanta, USA (Emory
107 Subgroup) (eTable 2 in Supplement). For these datasets, CXRs without lung lesions and cardiomegaly
108 were chosen after evaluations of structured radiological reports and labels. Individuals in the Emory
109 subgroup were selected based on having normal results in both CXR and echocardiography.

110 The study enrolled five disease groups including the VHD group (n=9964), patients evaluated for
111 CAD with coronary computed tomography angiography (CCTA) (CAD group, n=32,900),¹⁶
112 individuals who had undergone surgery for atrial or ventricular septal defects (CHD group, n=1299),
113 patients confirmed with thoracic aortic aneurysms by computed tomography (Aneurysm group,
114 n=294), and patients with biopsy-proven mediastinal masses (Mass group, n=110). The VHD group
115 was recruited from three institutions: Asan Medical Center, Severance Hospital, and Emory University
116 Medical Center, while the rest were from Asan Medical Center. Further details about each disease
117 subgroup are provided in the Supplement (eTable 3-5 and eFigure 2) and summarized in **Table 1**. The
118 VHD group was further categorized into the aortic stenosis (AS), aortic regurgitation (AR), mitral
119 stenosis (MS), mitral regurgitation (MR), and tricuspid valve (TV) subgroups. The CAD group data,
120 which was used for the prognostication testing in this study, included a median follow-up of 2.9 years
121 (interquartile range, 1.0–4.5) and was segmented into significant CAD subgroups based on >50%
122 stenosis observed in CCTA.¹⁶ The primary long-term clinical outcome was the composite of death
123 from any cause or myocardial infarction at 5 years after CCTA.¹⁶ The Aneurysm group was composed
124 of patients with an ascending aorta greater than 4.5 cm or a descending aorta/arch larger than 4 cm as
125 confirmed by CT. The Mass group retrospectively enrolled patients with mediastinal masses
126 confirmed by CT-guided biopsy.

127

128 **AI model**

129 The CVB analysis software has been previously validated against multi-institutional datasets.¹² This
130 AI software automatically delineates each CVB when a CXR is inputted. The width of each CVB was
131 calculated by measuring the distance from the midline of the CXR to the centerpoint of the height

132 **(Figure 2)**. Each CVB was named based on its normal anatomical location as follows: superior vena
133 cava/ascending aorta (SVC/AO), right atrium (RA), aortic arch (Arch), pulmonary trunk (PT), left
134 atrial appendage (LAA), left ventricle (LV), descending aorta (DAO), and the carinal angle (the angle
135 between the lower borders of the right and left main bronchi). The definitions of each CVB are
136 detailed in eTable 6. For CVB analysis, only CXRs taken in the postero-anterior direction with the
137 patient standing and with proper lung inflation were analyzed. Therefore, a separate imaging filter was
138 developed to exclude inappropriate CXRs. Detailed information on the deep learning algorithm and
139 imaging analysis workflow is provided in the eMethods (eFigure 3 in Supplement). This AI model is
140 available for external validation and public use via our non-commercial research website
141 (www.adcstudy.com), which provides real-time CXR analysis capabilities (eFigure 4 in Supplement).

142

143 **Analysis of AI measurements**

144 While most of the extracted CVB metrics approximated a symmetrical distribution, some variations in
145 kurtosis across different metrics as well as skewness in DAO were noted (eFigure 5 and 6 in
146 Supplement). To account for these discrepancies, each CVB metric underwent a transformation to a
147 Box-Cox normal distribution using Generalized Additive Models for Location, Scale, and Shape.¹⁷
148 Percentile curves were plotted for individual measurements, and z-scores were computed.^{17 18} Then,
149 the dimensions of each CVBs were standardized into z-scores.

150

151 **Statistical analysis**

152 Continuous variables are presented as means and standard deviations, while categorical variables are
153 presented as counts and percentages. Z-scores for each disease group are shown along with their
154 means and 95% confidence intervals (CIs). The diagnostic performance of CVB metrics in detecting
155 specific diseases was evaluated using the area under the receiver operating characteristic (AUC),
156 calculated with the pROC package (version 1.18.5) and included sensitivity, specificity, accuracy,
157 positive predictive value (PPV), and negative predictive value (NPV) with cut-off point determined by
158 the maximum Youden index. Diagnostic performance was assessed for the VHD, CAD, and CHD
159 groups, as well as for subgroups within VHD. For each disease category, a control group three times

160 the size of the disease group was randomly selected from the Normal Korean cohort. Multivariate
161 logistic regression analysis was used to identify CVBs significantly associated with the presence of
162 disease. Only CVB metrics that demonstrated a p-value <0.01 in univariate analysis and had low inter-
163 correlations ($r < 0.2$) were included in the multivariate analysis. The multivariate model was developed
164 using 60% of the randomly divided data and validated using the remaining 40%.

165 For the CAD group, Kaplan–Meier survival analyses were conducted using the survival package
166 (version 3.5.5), and Cox proportional-hazards regression models were used to examine the relationship
167 between CVB z-scores and patient outcomes, independent of known cardiovascular risk factors. These
168 analyses focused on the composite outcome of death from any cause or myocardial infarction
169 following CCTA. The Framingham Risk Score, body mass index (BMI), the presence of diabetes
170 mellitus, estimated glomerular filtration rate, symptoms at CCTA, and obstructed CAD (defined as
171 $\geq 50\%$ diameter stenosis) on CCTA were incorporated into the multivariate regression models,
172 consistent with previously published results.¹⁶ The CVB z-scores were categorized as follows: z-score
173 < -1 , $-1 \leq \text{z-score} < 0$, $0 \leq \text{z-score} < 1$, $1 \leq \text{z-score} < 2$, and $\text{z-score} \geq 2$.

174

175 **RESULTS**

176 **Study population**

177 The study population comprised 96,129 individuals in the normal cohorts and 44,567 patients in the
178 disease cohorts (**Table 1, Figure 1**). The mean age ranged from 46.5 years in the CHD group to 59.4
179 years in the Aneurysm group. The VHD group included 1432 AS (14.4%), 1756 AR (17.6%), 2897
180 MS (29.1%), 2971 MR (29.8%), 785 TV disease (7.9%), 72 PV disease (0.7%), and 51 multi-valve
181 disease (0.5%) cases (eTable 7 in Supplement). Echocardiography results show LV ejection fraction
182 and other cardiac dimensions, with disease groups often showing enlarged measurements compared to
183 normal.

184

185 **Normal range of CVBs**

186 eTable 8 in Supplement summarizes the normal ranges for CVBs on postero-anterior CXR for
187 different age groups in both Korean and American populations according to sex. **Figure 3** presents a
188 set of graphs depicting age-related percentile curves for various CVBs in normal individuals; detailed
189 graphs for Normal American and Korean cohorts were provided in the eFigure 7-10 in Supplement.
190 For both populations, the CT ratio tends to increase with age; similarly, the diameters for SVC/AO,
191 RA, Arch, LV, and DAO also increased with age, reflecting physiological changes in the
192 cardiovascular system as age advances. Inter-cohort comparisons revealed slightly larger CVBs in the
193 American group, differences that were mitigated after adjusting for CT ratio.

194

195 **Z-scores of CVBs in disease groups**

196 In the analysis of disease groups, z-scores for CVB were generally elevated, with the VHD and CHD
197 groups displaying significantly higher z-scores compared to the CAD group (**Figure 4** and eTable 9 in
198 Supplement). Specifically, the mean z-scores for the CT ratio were 0.39 in CAD, 1.27 in CHD, and
199 1.40 in VHD. **Figure 4** highlights the variations in z-scores across diseases, showcasing the disease-
200 specific changes in CVB parameters. MS, often accompanied by left atrial enlargement, showed
201 marked increases in the LAA (z-score=1.54) and carinal angle (z-score=1.10) as a result of the left
202 atrial pushing upwards; this was in marked contrast to AS where the increase in the SVC/AO (z-

203 score=1.02) indicated dilation of the ascending aorta. In CHD, including atrial or ventricular septal
204 defects, the z-score of the aortic arch (0.01) was relatively low, reflecting the reduced cardiac output
205 of the left heart due to left-to-right shunt disease. The aortic aneurysm group showed significant
206 increases in the arch (1.95) and DAO (2.65) z-scores, indicating aneurysmal changes. Mediastinal
207 mass conditions also demonstrated elevated z-scores, especially for the SVC/AO (1.04) and the
208 pulmonary trunk (1.03), which may indicate a mass shadow or compression caused by the tumor.

209

210 **Diagnostic performance**

211 The diagnostic evaluation of CVBs highlighted the CT ratio z-score as a robust metric across VHD,
212 CAD, and CHD groups (**Figure 5**). The AUC for detecting VHD using the CT ratio reached 0.79 (95%
213 CI, 0.78–0.80), which was increased to 0.82 (95% CI, 0.82–0.83) when combined with RA and LV
214 metrics. CHD detection benefited from a CT ratio AUC of 0.77 (95% CI, 0.74–0.79), which improved
215 to 0.81 (95% CI, 0.79–0.84) when PT and carinal angle were added. Among the subgroups of VHD,
216 TV disease detection had the highest AUC of 0.87 (95% CI, 0.84–0.89) using the CT ratio. Detailed
217 information on demographics, AUC, sensitivity, specificity, cut-off, PPV, and NPV is provided in
218 eTable 10-17 in Supplement.

219

220 **Prognostic value**

221 In the cohort of 32,900 CAD patients, there were 390 (1.18%) instances of all-cause death or
222 myocardial infarctions. CT ratio z-scores indicated an increasing risk with higher scores (**Figure 6**).
223 Patients with a CT ratio z-score of 2 or higher were at a significantly elevated risk (adjusted HR 3.73,
224 95% CI, 2.09–6.64), showing a higher percentage of cumulative events (4.6% vs. 0.6%, $p<0.001$) over
225 5 years compared to the reference group with a z-score less than -1 (HR 1.00). Elevated risks were
226 also observed with higher z-scores (≥ 2) for SVC/AO, RA, DAO, and carinal angle, while the Arch, PT,
227 LAA, and LV z-scores not reaching statistical significance (eTable 18 and eFigure 11-18 in
228 Supplement).

229

230 **Case examples**

231 We presented eight CXR case examples (eFigure 19-26 in Supplement), illustrating the application of
232 z-score mapping in diagnosing various cardiomeastinal diseases. The cases span a range of
233 conditions, including AS, MS, AR, atrial septal defect, aortic aneurysms, and mediastinal masses.

234

235 **DISCUSSION**

236 In the ADC study, we established normal values for CVBs and introduced a new methodology for
237 utilizing CXRs in cardiovascular disease diagnosis. Our main findings are as follows. First, z-score
238 mapping for CVBs was feasible in disease diagnosis. In certain cases, combining different CVBs
239 enhanced diagnostic accuracy beyond the CT ratio. Second, variations in z-scores, reflecting the
240 underlying disease pathophysiology, indicate that CXRs could be useful in classifying diseases, such
241 as distinguishing between aortic and mitral valve diseases. As demonstrated through our case
242 presentations, the changes in individual CVB z-scores may be correlated with the pathophysiological
243 changes observed in patients' echocardiograms or CT scans. The z-score mapping allows for a more
244 objective and quantifiable method of interpretation compared to traditional approaches to CXR
245 analysis. Lastly, measures of CVB, including the CT ratio, showed potential in predicting clinical
246 outcomes, adding value to traditional risk scoring systems.

247 Regarding the quantitative analysis of CXR, previous studies have focused on automatically
248 extracting the CT ratio¹⁹⁻²² and biological age²³ from CXRs using AI. As demonstrated in the ADC
249 study, the variability of the CT ratio's normal values based on age and sex indicates limitations in
250 applying a single cutoff 0.5. Moreover, conditions such as pulmonary trunk and ascending aortic
251 dilatation cannot be adequately assessed by the CT ratio alone. The significance of this ADC study lies
252 in standardizing various CVBs into a single parameter of z-score, not just the CT ratio, particularly
253 showing some success in making differential diagnoses that were not previously possible with the CT
254 ratio. Extracting biological age from CXR has shown promising prognostic value when added to
255 existing cardiovascular risk matrices, offering a potential new utility for CXR.²³ Since, CXR-derived
256 biological age and CVB z-scores are numerical data and likely independent, combining them could
257 offer potential for clinical practice and research applications.

258 The use of “end-to-end” supervised learning, where AI directly learns from CXRs with
259 abnormalities compared to a control group, is a widely adopted approach in current AI research. This
260 method has been extensively applied in the field of cardiovascular disease to predict conditions such
261 as acute chest pain syndrome²⁴, aortic dissection²⁵, LV systolic dysfunction⁶, structural LV disease⁷,
262 valvular heart disease⁵, aortic stenosis²⁶, and atrial fibrillation²⁷ using CXRs. Other studies have also
263 tried to predict the 10-year risk for major adverse cardiovascular events using CXRs.⁸ These studies
264 often employ saliency maps to improve the explainability of AI, indicating the specific areas of the
265 image that the AI prioritized to reach its decision. However, saliency maps can struggle with the
266 precise localization of abnormalities and may pose interpretative challenges when applied to diseases
267 not included in the algorithm's training.⁹ Z-score mapping, by providing interpretable numerical values
268 independent of specific diseases, can help overcome these limitations, offering broader applicability
269 across various cardiomedastinal conditions. This advancement may offer a modernized approach to
270 interpreting CXRs, aligning with clinicians' preference for quantifiable metrics, such as blood tests and
271 echocardiographic parameters. Moreover, this numerical approach facilitates a more objective
272 comparison during the follow-up of CXRs, making it easier to interpret changes over time in a
273 patient's condition.

274 For the utilization of z-score mapping of CXR in real-world clinical practice, it is crucial to
275 establish the most appropriate clinical application scenarios. For example, z-score mapping of CXRs
276 could serve as a gatekeeper before proceeding to more costly and complex tests such as
277 echocardiography. Another promising scenario could involve using z-score mapping of CXRs as a
278 screening tool to detect left-to-right shunt diseases before they progress to irreversible pulmonary
279 hypertension. Such applications could significantly enhance the utility of CXR, providing a cost-
280 effective, accessible, and non-invasive method. Particularly, using CXRs for VHD or CHD in
281 screening scenarios could be a viable alternative in underdeveloped countries where healthcare
282 infrastructure is insufficient.²⁸

283 This study has the following limitations: First, the CVB analysis is subject to limitations of the
284 CXR modality compared to echocardiography or CT. As demonstrated in Case 4 (ASD) and Cases 6
285 and 7 (mediastinal mass), CVBs can be influenced by adjacent structures. Therefore, the interpretation

286 of CVB analysis must be based on understanding of the specific disease's pathophysiology and
287 topographical anatomical knowledge in CXR. Second, although this study presents diagnostic
288 performance, z-score pattern analysis, and prognostic value, it has not provided definitive cut-off
289 values refined enough for application in actual practice. This is because, although the normal ranges
290 and disease cohorts included data from multiple institutions, they did not encompass a wide variety of
291 ethnicities and real-world conditions, including disease groups. Future research should conduct more
292 extensive studies across a wide range of clinical application scenarios.

293 The ADC study has introduced a fully automated, deep learning-derived z-score analysis of CXR
294 showed potential in detecting, classifying, and stratifying the risk of cardiovascular abnormalities.
295 Further research is needed to determine the most beneficial clinical scenarios for this method.

296

297 **Acknowledgements:** Professor Tae-Hwan Lim provided critical feedback, expertise, and
298 encouragement for the ADC study.

299

300 **Author contributions:** DHY, SHP, and YHK conceived and designed the study. JGL, GJ, and HO
301 developed and applied the deep learning model. TJJ, HJK, JEL, JWK, YA, SML, JBS, MSC, JMA,
302 DWP, JBK, CK, YJS, IC, MA, CDC, and EJC provided datasets. SK, HK, and JBL performed
303 statistical analyses. DHY, JGL, TJJ, and YHK drafted the manuscript. DHY and YHK supervised the
304 study. All authors contributed to the acquisition and interpretation of data, and critical revision of the
305 manuscript. DHY and YHK had access to and verified all the data in the study.

306

307 **Data sharing:** AI software developed for this study is freely available on the ADC study website
308 (www.adcstudy.com) for external validation. The patient-level data collected during the study will not
309 be made publicly accessible. However, the research team is open to considering collaborative projects
310 and specific data-sharing requests. Inquiries regarding data access should be directed to the lead
311 investigator, Dong Hyun Yang.

312

313 **Declaration of interests:** DHY and JGL reported holding a USA patent (11,783,477 B2) related to
314 this work. All other authors have reported that they have no relevant relationships to disclose
315 regarding the contents of this paper.

316

317 **Funding/Support:** This research was supported by a grant of the Korea Health Technology R&D
318 Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of
319 Health & Welfare, Republic of Korea (grant number: HI18C2383)

320


321 **REFERENCES**

- 322 1. Yun J, Ahn Y, Cho K, et al. Deep Learning for Automated Triaging of Stable Chest Radiographs in
323 a Follow-up Setting. *Radiology* 2023;309(1):e230606. doi: 10.1148/radiol.230606
- 324 2. Hwang EJ, Park CM. Clinical Implementation of Deep Learning in Thoracic Radiology: Potential
325 Applications and Challenges. *Korean J Radiol* 2020;21(5):511-25. doi: 10.3348/kjr.2019.0821
- 326 3. Wu K, Wu E, Theodorou B, et al. Characterizing the Clinical Adoption of Medical AI Devices
327 through U.S. Insurance Claims. *NEJM AI* 2024;1(1):AIoa2300030. doi:
328 doi:10.1056/AIoa2300030
- 329 4. D'Ancona G, Massussi M, Savardi M, et al. Deep learning to detect significant coronary artery
330 disease from plain chest radiographs AI4CAD. *Int J Cardiol* 2023;370:435-41. doi:
331 10.1016/j.ijcard.2022.10.154 [published Online First: 20221105]
- 332 5. Ueda D, Matsumoto T, Ehara S, et al. Artificial intelligence-based model to classify cardiac
333 functions from chest radiographs: a multi-institutional, retrospective model development and
334 validation study. *Lancet Digit Health* 2023;5(8):e525-e33. doi: 10.1016/S2589-
335 7500(23)00107-3 [published Online First: 20230706]
- 336 6. Hsiang CW, Lin C, Liu WC, et al. Detection of Left Ventricular Systolic Dysfunction Using an
337 Artificial Intelligence-Enabled Chest X-Ray. *Can J Cardiol* 2022;38(6):763-73. doi:
338 10.1016/j.cjca.2021.12.019 [published Online First: 20220107]
- 339 7. Bhave S, Rodriguez V, Poterucha T, et al. Deep learning to detect left ventricular structural
340 abnormalities in chest X-rays. *Eur Heart J* 2024 doi: 10.1093/eurheartj/ehad782 [published
341 Online First: 20240320]
- 342 8. Weiss J, Raghu VK, Paruchuri K, et al. Deep Learning to Estimate Cardiovascular Risk From Chest
343 Radiographs : A Risk Prediction Study. *Ann Intern Med* 2024 doi: 10.7326/M23-1898
344 [published Online First: 20240326]
- 345 9. Arun N, Gaw N, Singh P, et al. Assessing the Trustworthiness of Saliency Maps for Localizing
346 Abnormalities in Medical Imaging. *Radiol Artif Intell* 2021;3(6):e200267. doi:
347 10.1148/ryai.2021200267 [published Online First: 20211006]
- 348 10. Libby P. Braunwald's heart disease : a textbook of cardiovascular medicine. Twelfth edition ed.
349 Amsterdam: Elsevier 2021.
- 350 11. Yang DH, Seo JB, Lee IS, et al. Displaced aortic arch sign on chest radiographs: a new sign for the
351 detection of a left paratracheal esophageal mass. *Eur Radiol* 2005;15(5):936-40. doi:
352 10.1007/s00330-004-2540-9 [published Online First: 20041120]
- 353 12. Kim C, Lee G, Oh H, et al. A deep learning-based automatic analysis of cardiovascular borders on
354 chest radiographs of valvular heart disease: development/external validation. *Eur Radiol*
355 2022;32(3):1558-69. doi: 10.1007/s00330-021-08296-9 [published Online First: 20211013]
- 356 13. Wang X, Peng Y, Lu L, et al. ChestX-Ray8: Hospital-Scale Chest X-Ray Database and
357 Benchmarks on Weakly-Supervised Classification and Localization of Common Thorax
358 Diseases. 2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR): IEEE
359 Computer Society, 2017:3462-71.
- 360 14. Chexpert: A large chest radiograph dataset with uncertainty labels and expert comparison.
361 Proceedings of the AAAI conference on artificial intelligence; 2019.
- 362 15. Ahn I, Na W, Kwon O, et al. CardioNet: a manually curated database for artificial intelligence-
363 based research on cardiovascular diseases. *BMC Med Inform Decis Mak* 2021;21(1):29. doi:
364 10.1186/s12911-021-01392-2 [published Online First: 20210128]
- 365 16. Cho MS, Roh JH, Park H, et al. Practice Pattern, Diagnostic Yield, and Long-Term Prognostic
366 Impact of Coronary Computed Tomographic Angiography. *J Am Heart Assoc*
367 2020;9(18):e016620. doi: 10.1161/JAHA.120.016620 [published Online First: 20200908]
- 368 17. Rigby RA, Stasinopoulos DM. Using the Box-Cox t distribution in GAMLSS to model skewness
369 and kurtosis. *Statistical Modelling* 2006;6(3):209-29. doi: 10.1191/1471082X06st122oa
- 370 18. Kac G, Carilho TRB, Rasmussen KM, et al. Gestational weight gain charts: results from the
371 Brazilian Maternal and Child Nutrition Consortium. *Am J Clin Nutr* 2021;113(5):1351-60.
372 doi: 10.1093/ajcn/nqaa402

- 373 19. Saiviroonporn P, Rodbangyang K, Tongdee T, et al. Cardiothoracic ratio measurement using
374 artificial intelligence: observer and method validation studies. *BMC Med Imaging*
375 2021;21(1):95. doi: 10.1186/s12880-021-00625-0 [published Online First: 20210607]
- 376 20. Kim D, Lee JH, Jang MJ, et al. The Performance of a Deep Learning-Based Automatic
377 Measurement Model for Measuring the Cardiothoracic Ratio on Chest Radiographs.
378 *Bioengineering (Basel)* 2023;10(9) doi: 10.3390/bioengineering10091077 [published Online
379 First: 20230912]
- 380 21. Thiam P, Kloth C, Blaich D, et al. Segmentation-based cardiomegaly detection based on semi-
381 supervised estimation of cardiothoracic ratio. *Sci Rep* 2024;14(1):5695. doi: 10.1038/s41598-
382 024-56079-1 [published Online First: 20240308]
- 383 22. Fan W, Yang Y, Qi J, et al. A deep-learning-based framework for identifying and localizing
384 multiple abnormalities and assessing cardiomegaly in chest X-ray. *Nat Commun*
385 2024;15(1):1347. doi: 10.1038/s41467-024-45599-z [published Online First: 20240214]
- 386 23. Raghu VK, Weiss J, Hoffmann U, et al. Deep Learning to Estimate Biological Age From Chest
387 Radiographs. *JACC Cardiovasc Imaging* 2021;14(11):2226-36. doi:
388 10.1016/j.jcmg.2021.01.008 [published Online First: 20210317]
- 389 24. Kolossvary M, Raghu VK, Nagurney JT, et al. Deep Learning Analysis of Chest Radiographs to
390 Triage Patients with Acute Chest Pain Syndrome. *Radiology* 2023;306(2):e221926. doi:
391 10.1148/radiol.221926 [published Online First: 20230117]
- 392 25. Lee DK, Kim JH, Oh J, et al. Detection of acute thoracic aortic dissection based on plain chest
393 radiography and a residual neural network (Resnet). *Sci Rep* 2022;12(1):21884. doi:
394 10.1038/s41598-022-26486-3 [published Online First: 20221219]
- 395 26. Ueda D, Yamamoto A, Ehara S, et al. Artificial intelligence-based detection of aortic stenosis from
396 chest radiographs. *Eur Heart J Digit Health* 2022;3(1):20-28. doi: 10.1093/ehjdh/ztab102
397 [published Online First: 20211207]
- 398 27. Matsumoto T, Ehara S, Walston SL, et al. Artificial intelligence-based detection of atrial
399 fibrillation from chest radiographs. *Eur Radiol* 2022;32(9):5890-97. doi: 10.1007/s00330-022-
400 08752-0 [published Online First: 20220331]
- 401 28. Yuyun MF, Sliwa K, Kengne AP, et al. Cardiovascular Diseases in Sub-Saharan Africa Compared
402 to High-Income Countries: An Epidemiological Perspective. *Glob Heart* 2020;15(1):15. doi:
403 10.5334/gh.403 [published Online First: 20200212]
- 404

405 **FIGURE LEGENDS**

406 **Figure 1. Study workflow**



407

408 AI=artificial intelligence. AMC=Asan Medical Center. CAD=coronary artery disease.


409 CHD=congenital heart disease. CheXpert=Chest eXpert (public dataset from Stanford University

410 Hospital). CV=cardiovascular. CXR=chest X-ray. Emory=Emory University Hospital. KUMH=Korea

411 university Ansan Hospital. NIH=National Institute of Health Clinical Center. SNUBH=Seoul National

412 University Bundang Hospital. Yonsei=Yonsei University Severance Hospital.

413 **Figure 2. Z-score mapping process for cardiovascular borders in chest X-rays**



414

415 1. A standard postero-anterior chest X-ray is used as the input for the AI analysis.

416 2. AI algorithms automatically identify and delineate the CVBs on the chest X-ray.

417 3. The software measures the dimensions from the midline to key points on the CVBs to calculate the

418 cardiothoracic (CT) ratio and the dimensions of individual CVBs. The width of each CVB is defined

419 as the distance between the center points of each CVB and the midline of the CXR. The CT ratio was

420 calculated by dividing the maximum width of the right lower CVB (corresponding to the right atrium)

421 and the left lower cardiovascular border (corresponding to the left ventricle) by the maximal horizontal

422 thoracic diameter.

423 4. The measurements are then standardized into z-scores based on the normal range, allowing for

424 comparison according to age and sex.

425 LAA=left atrial appendage. SVC/AO=superior vena cava/ascending aorta.


426

427

428

429
430


Figure 3. Age-related percentile curves for cardiovascular borders in normal chest X-ray.



431

432 (A)

433



434

435 (B)

436 Percentile graphs of cardiovascular borders according to age for normal men (A) and women (B). The


437 data in red or blue represents Normal Korean individuals, and the data overlapped in gray represents

438 that of Normal Americans.

439

440

441 **Figure 4. Comparative z-score forest plot for disease classification**
 442



443

444 Each parameter is represented by a horizontal line, with data points indicating the mean z-score and
 445 error bars showing 95% confidence intervals.


446 (A) Comparison across different disease groups: coronary artery disease, congenital heart disease, and
 447 valvular heart disease.

448 (B) Comparison across specific valvular heart disease: aortic stenosis, mitral stenosis, and tricuspid
 449 valve disease.

450

451


452 **Figure 5. Performance of the z-score mapping of cardiovascular borders for the detection of**
453 **cardiovascular disease**
454



455
456 AUC=area under the receiver operating characteristic curve. CA=carinal angle. CT=cardiothoracic.
457 DAO=descending aorta. LAA=left atrial appendage. LV=left ventricle. PT=pulmonary trunk.
458 RA=right atrium. SVC=superior vena cava (SVC/aorta).

459
460

461 **Figure 6. All-cause death or myocardial infarction stratified by cardiothoracic ratio z-score**
 462



463

464 In the coronary artery disease group, all-cause death or myocardial infarction were stratified by z-

465 score categories of the CT ratio. Adjusted HRs were compared with the lowest z-score group (<-1).

466 (A) Percent of death or myocardial infarction and adjusted HR increased across ascending z-score

467 categories.

468 (B) Cumulative event rate for each z-score category of the CT ratio during a follow-up duration of 5

469 years.

470 CT=cardiothoracic. HR=hazard ratio.

471 **Table 1. Baseline characteristics and measurements of echocardiography and chest X-ray**

	Normal Korean n=71,493	Normal American n=24,636	VHD n=9964	CAD n=32,900	CHD n=1299	Aneurysm n=294	Mass n=110
Demographics							
Age, years	54.2 (11.4)	46.3 (16.5)	56.9 (15.4)	57.2 (10.0)	46.5 (14.2)	59.4 (13.9)	47.4 (18.4)
Male sex (%)	42932 (60.1)	13566 (55.1)	4304 (43.2)	20047 (60.9)	482 (37.1)	214 (72.8)	54 (49.1)
Height, cm	164.1 (8.7)	NA	160.5 (9.2)	164.4 (8.7)	161.8 (9.1)	167.2 (10.1)	90.7 (29.4)
Weight, kg	63.8 (10.7)	NA	60.1 (10.9)	66.6 (11.3)	59.5 (11.3)	67.6 (12.4)	65.7 (13.3)
Body mass index, kg/m ²	23.6 (2.9)	29.3 (9.2)*	23.4 (3.4)	24.5 (3.0)	22.6 (3.3)	24.1 (3.7)	24.3 (3.9)
Body surface area, m ²	1.70 (0.18)	NA	1.64 (0.18)	1.74 (0.18)	1.63 (0.19)	1.77 (0.20)	1.94 (1.97)
Echocardiography							
LV EDV index, mL/m ²	83.4 (20.8)	NA	105.1 (49.7)	89.2 (26.4)	87.4 (29.7)	109.3 (45.9)	90.7 (29.4)
LV ESV index, mL/m ²	30.8 (8.6)	NA	45.8 (32.5)	33.5 (13.0)	34.7 (15.5)	47.1 (32.4)	34.2 (16.7)
LV ejection fraction, %	63.1 (3.7)	61.3 (4.98)*	59.4 (10.1)	62.6 (8.3)	60.9 (7.1)	59.0 (9.4)	62.8 (6.2)
Ascending aorta, mm	32.1 (3.5)	NA	32.9 (7.0)	33.1 (6.7)	31.4 (4.4)	36.9 (5.3)	32.4 (4.5)
Chest X-ray							
Acceptance rate, %	98.2 (71,493/72,772)	96.8 (24,636/25,444)	96.2 (9964/10,357)	95.5 (32,900/34,446)	97.3 (1299/1335)	89.9 (294/327)	98.2 (110/112)
CT ratio	0.48 (0.05)	0.47 (0.06)	0.56 (0.08)	0.49 (0.06)	0.55 (0.08)	0.56 (0.07)	0.49 (0.05)
SVC/AO, mm	28.4 (6.8)	29.3 (8.5)	32.6 (9.4)	29.7 (7.2)	29.8 (9.2)	37.8 (11.3)	36.3 (12.4)
Right atrium, mm	39.1 (7.8)	41.4 (9.4)	46.2 (11.3)	40.8 (8.2)	44.1 (12.4)	48.0 (11.9)	40.8 (8.7)
Aortic arch, mm	38.3 (6.7)	35.3 (8.3)	39.4 (8.2)	39.5 (6.8)	37.2 (8.0)	52.6 (14.0)	40.9 (9.4)
Pulmonary trunk, mm	38.5 (6.4)	37.8 (7.9)	43.3 (8.6)	39.8 (6.8)	47.0 (9.2)	46.2 (10.4)	45.3 (10.1)
Left atrial appendage, mm	46.4 (7.3)	46.7 (9.1)	53.9 (10.2)	48.1 (7.8)	58.1 (10.6)	54.1 (10.8)	53.2 (10.0)
Left ventricle, mm	84.6 (10.5)	85.6 (14.2)	96.6 (14.0)	88.7 (11.3)	98.7 (14.4)	101.9 (14.2)	85.9 (10.9)
Descending aorta, mm	33.3 (8.6)	29.1 (9.5)	42.2 (11.2)	36.2 (9.4)	35.0 (11.5)	56.3 (16.0)	35.2 (9.5)
Carinal angle, degree	71.1 (8.7)	72.3 (9.6)	79.3 (11.2)	72.1 (9.6)	77.7 (11.1)	80.7 (12.1)	77.9 (8.9)

472 Values are mean (SD) or number (%). CT = cardiothoracic; DAO = descending thoracic aorta; EDV = end-diastolic volume; ESV = end-systolic volume; LV
 473 = left ventricle; NA = not available; SVC/AO = superior vena cava/ascending aorta. Acceptance rate represents the proportion of inputted chest postero-
 474 anterior X-rays that were successfully analyzed and found to be free of lung hyper- or hypo-inflation. Body mass index and LV ejection fraction in the Normal
 475 American from Emory University subgroup.